URI1 Antibody (YA1207)
(Synonyms: Protein NNX3; RMP; URI; NNX3; C19orf2; PPP1R19)Based on 1 Customer Validation
URI1 Antibody (YA1207) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to URI1.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
IHC-P
-
Reactivity :
Human
-
Formulation:
Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide, 0.05% BSA.
-
Conjugation:
Non-conjugated
Applications
| Application |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
|---|---|
| Dilution Ratio | 1:100-1:200 |
Product Details
URI1 Antibody (YA1207) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to URI1.
-
Host Rabbit
-
Clonality Recombinant,Monoclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 60 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 60 kDa
A synthesized peptide derived from human C19orf2
Endogenous
Affinity Purified
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide, 0.05% BSA.
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
URI1 is involved in gene transcription regulation. Acts as a transcriptional repressor in concert with the corepressor UXT to regulate androgen receptor (AR) transcription. May act as a tumor suppressor to repress AR-mediated gene transcription and to inhibit anchorage-independent growth in prostate cancer cells. Required for cell survival in ovarian cancer cells. Together with UXT, associates with chromatin to the NKX3-1 promoter region. Antagonizes transcriptional modulation via hepatitis B virus X protein; Plays a central role in maintaining S6K1 signaling and BAD phosphorylation under normal growth conditions thereby protecting cells from potential deleterious effects of sustained S6K1 signaling. The URI1-PPP1CC complex acts as a central component of a negative feedback mechanism that counteracts excessive S6K1 survival signaling to BAD in response to growth factors. Mediates inhibition of PPP1CC phosphatase activity in mitochondria. Coordinates the regulation of nutrient-sensitive gene expression availability in a mTOR-dependent manner. Seems to be a scaffolding protein able to assemble a prefoldin-like complex that contains PFDs and proteins with roles in transcription and ubiquitination
-
Subcellular Localization
Nucleus; Cytoplasm; Mitochondrion; Cell projection, dendrite
-
Expression
Tissue_specificity:Ubiquitous. Expressed in ovarian cancers (at protein level) . Expressed strongly in skeletal muscle. Expressed weakly in brain, heart, pancreas and in prostate epithelial cells -
Isoforms & Post-Translational Modification
O94763 has 4 isomers: O94763-1: 59832 Da (predicted); O94763-2: 51247 Da (predicted); O94763-3: 56978 Da (predicted); O94763-4: 53447 Da (predicted).
Phosphorylated. Phosphorylation occurs essentially on serine residues. Phosphorylation occurs in response to androgen treatment in prostate cancer cells in a mTOR-dependent manner. Phosphorylated; hyperhosphorylated in mitochondria in a mTORC-dependent signaling pathway. Phosphorylated at Ser-372 by RPS6KB1 in a growth factor- and rapamycin-dependent manner. S6K1-mediated mitochondrial phosphorylation at Ser-372 disrupts the URI1-PPP1CC complex in the mitochondrion, relieves PPP1CC phosphatase inhibition activity and hence engages a negative feedback diminishing RPS6KB1 kinase activity, preventing sustained S6K1-dependent signaling -
Subunit
Homodimer. Component of the PAQosome complex which is responsible for the biogenesis of several protein complexes and which consists of R2TP complex members RUVBL1, RUVBL2, RPAP3 and PIH1D1, URI complex members PFDN2, PFDN6, PDRG1, UXT and URI1 as well as ASDURF, POLR2E and DNAAF10/WDR92 (PubMed:31738558). Interacts with POLR2E/RPB5, RUVBL2 and RUVBL1 (PubMed:14615539, PubMed:9819440). Interacts with PFDN2, PFDN4 and STAP1; the interactions are phosphorylation-dependent and occur in a growth-dependent manner in the mitochondrion (PubMed:14615539). Interacts with UXT (PubMed:21730289). Interacts with PPP1CC; the interaction is phosphorylation-dependent and occurs in a growth factor-dependent manner (PubMed:21397856). Interacts (via the middle C-terminal region) with GTF2F1 and GTF2F2 (PubMed:12737519). Interacts with DMAP1 (PubMed:15367675). Interacts with TSC1 and TSC2 (PubMed:28561026). Interacts with PRPF8 and EFTUD2 in a ZNHIT2-dependent manner (PubMed:28561026)
-
SwissProt ID
-
Synonyms
Protein NNX3; RMP; URI; NNX3; C19orf2; PPP1R19
-
Research Field
Epigenetics and Nuclear Signaling
Documentation
-
Data Sheet (234 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
User Guide for Antibodies (1077 KB)